Guardant Health, Inc. has announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy. This study, results of which were published in Cancer Research Communications, evaluated the effectiveness of Guardant Reveal, a tissue-free monitoring tool, in detecting responses to immunotherapy across various solid tumor types in patients with advanced-stage cancer. The findings indicate that Guardant Reveal can identify non-responders to immunotherapy up to five months earlier than standard methods. The study involved over 500 patients and demonstrated a strong association between long-term patient outcomes and changes in tumor fraction measured through Guardant Reveal. These results underscore the potential of blood-based monitoring to improve treatment decision-making in cancer care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.